2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2840 Viral and atypical pathogen detection by tngs in pediatric hematological patients: Stratification by HSCT status and disease type

Changwen Xue, Chunhui Xu2, Yang Wan3, Wenyu Yang4, Xiaofan Zhu, MD5
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China, Tianjin Union Precision Medical Diagnostic Co., Ltd, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Background
Pediatric patients with hematological diseases are at high risk for respiratory infections due to immunosuppression. Targeted next-generation sequencing (tNGS) enables comprehensive pathogen detection, but the epidemiology of respiratory viral and atypical pathogens across different clinical contexts remains poorly characterized.

Methods
We retrospectively analyzed 970 tNGS samples from 579 pediatric hematological patients with suspected respiratory infections. Samples were stratified by hematopoietic stem cell transplantation (HSCT) status at sampling: HSCT group (136 patients, 230 samples) and non-HSCT group (497 patients, 740 samples); 54 patients contributed samples to both groups. Samples were further stratified by underlying disease type (benign vs. malignant). Detection rates of nine respiratory viruses, two atypical bacteria (Mycoplasma pneumoniae and Chlamydia pneumoniae), and Pneumocystis jirovecii were compared between groups. Neutrophil and lymphocyte counts were categorized according to clinical thresholds. Multivariable logistic regression was performed to identify independent factors associated with pathogen detection.

Results
The overall pathogen detection rate was comparable between HSCT and non-HSCT samples (41.7% vs. 37.2%, P = 0.212). However, malignant disease samples had significantly higher detection than benign disease samples (40.3% vs. 28.7%, P = 0.004). A clear gradient was observed across four subgroups: HSCT-malignant (46.1%), non-HSCT-malignant (38.9%), HSCT-benign (33.3%), and non-HSCT-benign (24.7%). Rhinovirus was the most frequently detected pathogen (142/371, 38.3%), followed by influenza virus (15.1%) and parainfluenza virus (14.3%). Adenovirus (4.3% vs. 1.1%, P = 0.001) and bocavirus (2.6% vs. 0.5%, P = 0.009) were significantly more common in HSCT samples. Within the HSCT group, rhinovirus predominated in malignant samples (17.1% vs. 5.1%, P = 0.011), while M. pneumoniae was more frequent in benign samples (7.7% vs. 1.3%, P = 0.013). Mixed infections (≥2 pathogens) were more frequent in HSCT samples (27.1% vs. 13.8%, P = 0.010). Seasonal distribution differed significantly among pathogens (P < 0.001), with influenza virus and RSV peaking in winter, rhinovirus in autumn, and bocavirus in spring. In univariate analysis, severe neutropenia was associated with lower pathogen detection (30.8% vs. 40.9%, P = 0.015), while lymphocyte levels showed no association. Multivariable regression identified malignant disease (OR = 1.86, P = 0.002) and HSCT status (OR = 1.46, P = 0.036) as independent risk factors, while older age (OR = 0.96 per year, P = 0.005) and summer season (OR = 0.57 vs. spring, P = 0.009) were protective. After adjustment, neither neutrophil nor lymphocyte counts remained significant (both P > 0.05). In an exploratory analysis of 442 samples with available immunoglobulin data, low IgA (OR = 1.92, P = 0.003) and low IgM (OR = 1.49, P = 0.045) were associated with higher detection rates.

Conclusions
Malignant disease, rather than HSCT status alone, is the dominant risk factor for respiratory pathogen detection in pediatric hematological patients. HSCT recipients with malignant diseases represent the highest-risk subgroup (46.1% detection rate) and exhibit higher rates of mixed infections and specific viral vulnerabilities (adenovirus, bocavirus). Severe neutropenia is not independently associated with increased risk after multivariable adjustment, suggesting that broader immune dysfunction underlies the elevated risk in transplant recipients. Low IgA and IgM may increase pathogen susceptibility, warranting further investigation. These findings support risk-adapted surveillance and infection control strategies in pediatric hematology settings.

Changwen Xue: No relevant conflicts of interest to declare.